Neuroblastoma (NB) is the most common solid malignant tumor of childhood. NB belongs to the class of small round cell tumors (SRCTs), which includes other solid tumors such as Ewing's sarcoma (ES), malignant lymphoma and rhabdomyosarcoma. Since SRCTs are histologically ambiguous, it is necessary to identify reliable tumor markers by cytogenetic and molecular biological analyses to facilitate accurate diagnosis. Moreover, the prognosis for patients with NB is related to the age of patient and disease stage at diagnosis, and some biological characteristics of the tumor. In cases with advanced stage IV NB, bone marrow (BM) is a major site of metastasis, and monitoring for BM metastasis is very important while evaluating the efficacy of chemotherapy. Strong chemoradiotherapy with hematopoietic stem cell transplantation is used for the treatment of NB patients with a poor prognosis. 1, 2) Recent advances in reverse transcriptionpolymerase chain reaction (RT-PCR) techniques have enabled the detection of circulating tumor cells and BM micrometastases in NB patients. 3) Markers that accurately predict a good outcome are used to identify subsets of patients who may be candidates for a decrease in the intensity of cytotoxic therapy. 4) In a previous study, we demonstrated amplification of the mRNA for tyrosine hydroxylase (TH), which is the first and rate-limiting enzyme in catecholamine biosynthesis, by RT-PCR, enabling sensitive detection of even one NB cell among 10 5 negative cells. 5) We also examined three other genes to identify the most useful marker of NB. Of these, neuroendocrine protein gene product 9.5 (PGP9.5) is a neuron-specific protein that removes ubiquitin from ubiquitinated proteins and proteasomes, 6) while embryonic lethal, ab-normal vision, Drosophila-like 4 (ELAVL-4), or Hu antigen D (HuD), which belongs to the elav gene family of Drosophila melanogaster, have been reported to be highly specific for neuroectodermally derived tumors, 7) and GD2 synthetase (GALGT) catalyzes the transfer of 1,4-Nacetylgalactosamine to GD3 ganglioside and plays a key role in GD2 disialoganglioside biosynthesis. 8) As GALGT (b-1,4-N-acetylgalactosaminyl-transferase) is strongly expressed in neural crest-derived tumors, such as melanomas and NBs, it is believed that GALGT is a key enzyme required for GD2 synthesis. 9) This enzyme is frequently used as a molecular marker for the detection of minimal residual disease (MRD) in NB patients.
We report the results of the sensitivity and specificity of the four markers described above for the detection of MRD in cases of NB using various cell lines.
MATERIALS AND METHODS
Cell Lines Three NB cell lines (IMR-32, SK-N-SH, and NB-39), two ES cell lines (NCR-EW2, SCMC-ES1), and other tumor cell lines (breast cancer (MCF-7), hepatoma (Hep G2), two leukemia cell lines (Jurkat, HL-60)) were used. In addition, we examined two normal human samples (BM and PB cells). All cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 7.5% (W/V) sodium bicarbonate (GIBCO BAL) under 5% CO 2 at 37°C. Informed consent was obtained from the patient/volunteer (for the BM and PB cells) before they entered this study. The study underwent ethical review and approval ac-
Neuroblastoma (NB), which is a malignant tumor of young children derived from neural crest cells that occurs in children, exhibits a wide range of clinical behaviors, from spontaneous regression to rapid progression. Advanced NB patients have a poor prognosis, and recently, autologous bone marrow transplantation (BMT) and autologous peripheral blood stem cell transplantation (PBSCT) have been attempted to improve the prognosis of these patients. In this study, we attempted to detect the expression of tyrosine hydroxylase (TH), neuroendocrine protein gene product (PGP) 9.5, ELAVL-4 and GD2 synthetase (GALGT), all of which are highly expressed in NBs, by the reverse transcription-polymerase chain reaction (RT-PCR) technique in order to detect minimal residual disease (MRD) in the bone marrow (BM) and peripheral blood (PB). Analysis of various tumor cell lines (Ewing's sarcoma, hepatoma, leukemias, and breast cancer cell lines in addition to NBs), and human normal samples (BM and PB cells) revealed that TH was the most specific marker for the detection of NB.
On the other hand, PGP9.5 was the most sensitive marker, and was detected even when there was only one positive cell per 10 7 negative cells. We concluded that TH is a better marker before the diagnosis of NB while PGP9.5 is a better marker to detect MRD after the diagnosis. Here, we describe our results on useful markers to detect MRD in patients with NB.
cording to the guidelines of the institutional review board (IRB) of the College of Pharmacy, Nihon University.
RNA Extraction Total RNA was extracted from the 9 cancer cell lines and 2 human normal human bone marrow and peripheral blood cells (shown in Table 1 ) with the TRI ZOL reagent (Gibco BAL) by the acid-guanidium-phenol chloroform extraction method. 10) Reverse Transcription-Polymerase Chain Reaction (RT-PCR) RNA was reverse-transcribed to cDNA with the a Takara RNA PCR kit (AMV), Version 3.0 (Takara, Otsu, Japan) using oligo(dT) as the primers. The RT was carried out at 42°C for 30 min, followed by annealing at 99°C for 5 min, and finally holding at 4°C. The PCR amplifications were carried out on a Mastercycler (Eppendorf, Westbury, NY, U.S.A.). The PCR conditions were one cycle of template denaturing at 94°C for 2 min, followed by 30 cycles of denaturing at 94°C for 0.5 min, annealing at 65°C for 0.5 min, extension at 72°C for 1 min after the last cycle, and further extension for an additional 4 min at 72°C and 5 min at 5°C.
Analysis of the PCR Products An Agilent Technologies Bioanalyzer was used to accurately determine the band sizes of the PCR products and of human glyceraldehyde-3-phosphate dehydrogenase (h-GAPDH) as the internal marker. The primer sequences used for TH, PGP9.5, ELAVL-4 and GALGT are listed in Table 2 .
Detection of Sensitivity A NB cell line (NB-39) was examined as the positive control and a leukemia cell line (HL-60) as the negative control. We counted the cell number in each cell line and diluted the cultures to make suspensions containing one NB cell per 10 leukemia cells, one NB cell per 10 2 cells, one NB cell per 10 3 cells, one NB cell per 10 4 cells, one NB cell per 10 5 cells, one NB cell per 10 6 cells, and one NB cell per 10 7 cells. We investigated the sensitivity of detection of TH, PGP9.5, ELAVL-4, GALGT mRNA in the cell suspensions by RT-PCR.
RESULTS AND DISCUSSION
We examined 9 cancer cell lines and two normal human cell lines (BM and PB cells) to detect the products of TH, PGP9.5, ELAVL-4 and GALGT by RT-PCR (Table 1 ). The band sizes for TH, PGP9.5, ELAVL-4, GALGT and h-GAPDH (as the internal marker) were 299 bp, 370 bp, Fig. 1 ), respectively. The TH product was detected specifically only in the three NB cell lines (NB-39, IMR-32 and SK-N-SH), and not in the other tumor cell lines, namely, the cell lines derived from Ewing's sarcoma (ES) (NCR-EW2, SCMC-ES1) belonging to the class of SRCTs, hepatoma (Hep G2), breast cancer (MCF-7), or the two leukemias (Jurkat, HL-60) (Table 1, Fig.  1A) . The PGP9.5 product was detected in the three NB and two ES cell lines, but not in the other 4 tumor cell lines examined (Table 1, Fig. 1B) . The ELAVL-4 product was detected in the three NB, two ES and one breast cancer cell line (MCF-7) examined (Table 1, Fig. 1C ). The GALGT product was detected in all the cell lines examined, except one derived from leukemia (HL-60) (Table 1, Fig. 1D ). In contrast, none of the four tumor markers was detected in the normal human bone marrow (BM) or peripheral blood (PB) samples examined (Table 1, Figs. 1A-D) . While all the NB cell lines expressed all four genes, the only marker that was specifically expressed in only the NB cell lines was TH.
These results suggest that TH has the highest specificity of the four markers examined for the detection of NB and might, therefore, be the most useful tumor marker for distinguishing NB from not only other malignant tumors, but also from ES, which belongs to the class of SRCTs. Moreover, as TH could also not be detected in normal human BM and PB cells, it could be useful for detecting MRD in the BM and PB cells of NB patients.
Since BM is a major metastatic site and monitoring for BM metastasis is very important to determine the outcome of autologous BM transplantation (auto-BMT) and autologous PB stem cell transplantation (auto-PBSCT), 11) we examined the sensitivity of each marker for the detection of MRD by RT-PCR using a NB cell line (NB-39) as the positive control and a leukemia cell line (HL-60) as the negative control. In a previous study, we demonstrated the sensitivity of detecting the TH product, which could detect one NB cell per 10 5 negative cells, using a Bioanalyzer ( Fig. 2A) . Similarly, using a RT-PCR technique, we found that amplification of PGP9.5 was useful for identifying one NB cell per 10 7 HL-60 (negative cells), and that amplification of ELAVL-4 or GALGT was useful for identifying one NB cell per 10 3 negative cells ( Table 3 , Figs. 2B, C) . Therefore, PGP9.5 was the most sensitive marker among the markers examined for the identification of MRD in NB patients ( Table 3) .
As NB has a specific catecholamine metabolism, it may be more useful to detect TH, which is the first and rate-limiting enzyme of catecholamine synthesis. 5) PGP9.5 was also originally identified as a cytoplasmic marker for neurons and neuroendocrine cells. 12, 13) Functionally, PGP9.5 belongs to the ubiquitin C-terminal hydrolase (UCH) family. 14) This enzyme is a part of the cellular proteolytic pathway that regulates many cellular processes, including cell cycle progression and cell death. 15) It is a 212-amino acid, ubiquitin carboxyl-terminal hydrolase 14) which constitutes 1-2% of the total soluble brain proteins, 16) where it is localized exclusively in the neuronal cytoplasm. 17) It is widely expressed in neuronal tissues at all stages of neuronal differentiaton. 14, 18) It has been reported that PGP9.5 is also expressed in other cancers besides neuroendocrine tumors, and that the use of other neuroendocrine markers for the detection of NB would be desirable. 19, 20) ELAVL-4 has also been reported to be highly specifically expressed in neuroectodermal-cell-derived tumors, such as neuroblastoma. 21) GALGT has been reported to be strongly expressed in neural crest-derived tumors, such as melanoma and NB, 9) and the enzyme is frequently used as a molecular marker for the detection of MRD in the BM and PB cells of NB patients. Our results suggest that among the neuronal markers examined, TH has the best specificity for the detection of NB cells, and that it can be used to diagnose NB or to detect MRD in the BM and PB cells, even in patients without the diagnosis of NB. Moreover, PGP9.5 showed the best sensitivity among the markers examined, allowing the detection of even one NB cell per 10 7 negative cells, and it is very useful for the detection of MRD in them, but only in patients already diagnosed to have NB, because it has poorer specificity than TH.
Because the mixture ratio of tumor cells with normal cells has become low and the marrow functional recovery is faster, as compared with auto-BMT, auto-PBSCT has been used in the treatment of advanced NB patients. 21) However, the detection of MRD in PBSC by genetic analysis is necessary, because its transplantation succeed. Therapy failures in highrisk NB patients are also likely to be caused by tumor cells developing resistance to chemotherapy. 22) Moreover, the detection of tumor cells in a metastasis site (e.g., bone marrow) with high sensitivity would not only affect the official approval for the transplantation, but also the decisions related to further therapy and the frequency of recurrence.
Therefore, these two markers can be used for the detection of cancer cells in PBSC and BM for advanced NB patients and are useful for monitoring the response to chemotherapy and hematopoietic stem cell transplantation.
